Kavalactone yangonin induces autophagy and sensitizes bladder cancer cells to flavokawain A and docetaxel via inhibition of the mTOR pathway
Zhongbo Liu, U-Syn Ha, Ke Yu, Chunli Wu, Noriko Yokoyama, Xiaolin Zi
Kavalactone yangonin induces autophagy and sensitizes bladder cancer cells to flavokawain A and docetaxel via inhibition of the mTOR pathway
Consumption of kava (Piper methysticum Forst) has been linked to reduced cancer risk in the South Pacific Islands. Kavalactones are major bioactive components in kava root extracts, which have recently demonstrated anti-cancer activities. However, molecular mechanisms of kavalactones' anti-cancer action remain largely unknown. We have identified two kavalactones, yangonin and 5′ 6'-dehydrokawain, as potent inducers of autophagic cell death in bladder cancer cells. The effect of yangonin inducing autophagy is associated with increased expression of beclin and ATG5. In addition, yangonin increases the expression of LKB1 and decreases the phosphorylation of Akt, PRAS40, rpS6, p70S6K and 4E-BP1, leading to increased binding of 4E-BP1 to m7 GTP. The growth inhibitory effects of yangonin were attenuated inTSC1 or LKB1 knockout mouse embryonic fibroblasts, suggesting that TSC1 and LKB1 expression may contribute to optimal growth inhibition by yangonin. Furthermore, yangonin reduces the viability of bladder cancer cell lines derived from different stages of human bladder cancer, and acts synergistically with apoptosis-inducing agents such as docetaxel and flavokawain A. Our results support a novel anti-bladder cancer mechanism by yangonin and further studies are needed to assess the potential use of yangonin for bladder cancer prevention and treatment
yangonin / bladder cancer / autophagy / mTOR
[1] |
http://globocan.iarc.fr, accessed on 11/21/ 2016.
|
[2] |
Puzio-Kuter AM, Castillo-Martin M, Kinkade CW ,
Pubmed
|
[3] |
Abraham R, Pagano F, Gomella LG ,
Pubmed
|
[4] |
Roberts JT, von der Maase H, Sengeløv L ,
Pubmed
|
[5] |
von der Maase H , Hansen SW , Roberts JT ,
Pubmed
|
[6] |
Gallagher DJ, Milowsky MI, Bajorin DF . Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting[J].Cancer, 2008, 113(6): 1284–1293
Pubmed
|
[7] |
Fourth Symposium on Epidemiology and Cancer Registries in the Pacific Basin[J]. Proceedings of a symposium held in Kona, Hawaii, January 16-20, 1984.Natl Cancer Inst Monogr, 1985, 69: 1–282
Pubmed
|
[8] |
Meredith I, Sarfati D, Ikeda T ,
Pubmed
|
[9] |
Tuomilehto J, Zimmet P, Taylor R ,
Pubmed
|
[10] |
Steiner GG. The correlation between cancer incidence and kava consumption[J]. Hawaii Med J, 2000, 59(11): 420–422
Pubmed
|
[11] |
Li X, Liu Z, Xu X ,
Pubmed
|
[12] |
Zi X, Simoneau AR. Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice[J]. Cancer Res, 2005, 65(8): 3479–3486
Pubmed
|
[13] |
Narayanapillai SC, Balbo S, Leitzman P ,
Pubmed
|
[14] |
Li X, Yokoyama NN, Zhang S ,
Pubmed
|
[15] |
Pinner KD, Wales CT, Gristock RA ,
Pubmed
|
[16] |
Liu Z, Li X, Simoneau AR ,
Pubmed
|
[17] |
Liu Z, Antalek M, Nguyen L ,
Pubmed
|
[18] |
Liu H, He Z, Simon H . Protective role of autophagy and autophagy-related protein 5 in early tumorigenesis[J]. J Mol Med (Berl), 2015, 93(2):159–164.
Pubmed
|
[19] |
Kallifatidis G, Hoepfner D, Jaeg T ,
Pubmed
|
[20] |
Jung CH, Ro SH, Cao J ,
Pubmed
|
[21] |
Shorning BY, Griffiths D, Clarke AR . Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and epithelial-mesenchymal transition in the mouse bladder[J]. PLoS One, 2011, 6(1): e16209
Pubmed
|
[22] |
Singh YN. Kava: an overview[J]. J Ethnopharmacol, 1992, 37(1): 13–45
Pubmed
|
[23] |
Foliaki S, Best D, Akau'ola S ,
Pubmed
|
[24] |
Henderson BE, Kolonel LN, Dworsky R ,
Pubmed
|
[25] |
McConkey DJ, Lee S, Choi W ,
Pubmed
|
[26] |
Mo L, Zheng X, Huang HY ,
Pubmed
|
[27] |
Sibley K, Cuthbert-Heavens D, Knowles MA . Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma[J]. Oncogene, 2001, 20(6): 686–691
Pubmed
|
[28] |
Dinney CP, McConkey DJ, Millikan RE ,
Pubmed
|
[29] |
Seager CM, Puzio-Kuter AM, Patel T ,
Pubmed
|
[30] |
Motzer RJ, Escudier B, Oudard S ,
Pubmed
|
[31] |
Liu Z, Li X, Simoneau AR ,
Pubmed
|
[32] |
Morikawa Y, Koike H, Sekine Y ,
Pubmed
|
[33] |
Niu H, Wang J, Li H ,
Pubmed
|
[34] |
Shigematsu H, Yoshida K, Sanada Y ,
Pubmed
|
/
〈 | 〉 |